22
JUN
2017

NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds

Posted By :
Comments : Off
Debt Convertible at $0.25, $.50 and $1.00;  Secured By UK Property   BETHESDA, MD, June 22, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has closed a convertible debt exchange and financing transaction with a non-affiliated investor and has completed the payoff of the...
Read More
05
JUN
2017

Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today

Posted By :
Comments : Off
Updates to Include Both DCVax®-L Phase III Trial and DCVax®-Direct Phase I/II Trial BETHESDA, Md., June 5, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that this afternoon at 3:00 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in...
Read More
23
MAR
2017

NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors

Posted By :
Comments : Off
BETHESDA, Md., March 23, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that yesterday it closed on the $7.5 million financing it announced last Friday, March 17, 2017. The Company sold to several institutional investors securities totaling 28,843,692 shares, comprised of 18,843,692 common shares at $.26 per share,...
Read More
17
MAR
2017

NW BIO Announces Registered Direct Offering Of $7.5 Million

Posted By :
Comments : Off
BETHESDA, Md., March 17, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $7.5 million. In the transaction, the Company will sell approximately 28.8 million shares of common stock at a...
Read More
10
MAR
2017

NW Bio Reaches Agreement With Convertible Note Holders

Posted By :
Comments : Off
BETHESDA, MD, March 10, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors (“Whitebox”), holder of $11 million of NW Bio convertible senior notes. With these Notes otherwise...
Read More